JP Morgan Dr. Reddy’s laboratories have low weight with a target price of Rs 1,060. Analysts said Pharma Major’s public march was in the revenue line, but Ebitda estimated. According to him, low -weight ratings are on the weak core Ebitda margin, a decrease in India, the lack of visibility on the niche launch in the US and the semaglutide opportunity may be decent but the market is expected to be competitive.Citigroup has a purchase rating with a target price of Rs 430 on Biocon. Analysts said Biocon’s public number was weak as there was a decline in the pre-Gravlimid EBITDA margin. The company reported about 4% annual growth in biosimiler despite a strong market share expansion in ONCO assets, indicating a weak pricing landscape.Nomura has given a ‘buy’ rating on Zidus Life with a target price of Rs 1,140. Analysts said the company has received approval for the GCOPAXone, which estimates their market size $ 600 million. Apart from Teva, there are two common players for the same. They are Biocon and Dr. Reddy also expects additional competition from Reddy.McWery maintained her underperform rating on Swiggy with a target price for Rs 260. Calling the public number on the number ‘bad to worse’, he said that the results of the sweegy continued under the challenges for the forum. The management now expects a margin brake contributing to 3-5 quarters vs. 3-5 quarters under the guidance before receiving the same by December 2025. He also stated that the margin gap to eternal (zomato) continued to continue.Goldman Sachs has a purchase rating on Pidilite with a target price of Rs 3,475. Analysts stated that the company’s strong, near-dabble points continued to increase despite a silent environment. Management is optimistic about the development of FY26, which has improved some improvement in the widespread consumption environment. They also feel that B2B growth in the next 2-3 years is likely to be very strong.Disclaimer: The opinion, analysis and recommendations expressed here are of brokerage and do not reflect the views of the Times of India. Always consult a qualified investment advisor or financial planner before taking any investment decision.
